Objectives: Cytotoxic T-lymphocyte antigen (CTLA)-4 is a homolog of CD28, which is expressed only on activated T cells. It binds to accessory molecule B7 and mediates T-cell-dependent immune response. Signaling through CTLA-4 may down-regulate type 1 T-helper cell proliferation; moreover, some studies suggest that CTLA-4 might also deliver a positive signal to type 2 T-helper cell activation. Disruption of this delicate balance of immune regulation may lead to autoimmune diseases or atopic diseases. To evaluate the possible role of CTLA-4 polymorphisms in bronchial asthma, we investigated the association between polymorphisms (exon 1 ؉49 A/G, promoter ؊318 C/T) and atopy, asthma severity, and bronchial hyperresponsiveness in bronchial asthma patients and a group of healthy control subjects. Patients: Eighty-eight asthmatic patients and 88 healthy control subjects were studied. Measurements and results: Asthma severity assessment, methacholine challenge, allergy skinprick test, and serum total IgE measurements were performed. The genotypes of the CTLA-4 promoter (؊318 C/T) and exon 1 (؉49 A/G) in all subjects were determined using the polymerase chain reaction and restriction fragment length polymorphism. The CTLA-4 promoter (؊318 C/T) polymorphism was shown to be associated with asthma severity, but not with asthma, atopy, or bronchial hyperresponsiveness. A significant association was found between severe asthma and the T allele (p ‫؍‬ 0.037). The CTLA-4 exon 1 (؉49 A/G) polymorphism was shown to be associated with bronchial hyperresponsiveness, but not with asthma, atopy, or asthma severity. Asthmatic patients of the GG genotype had more hyperresponsive airways than those with the AG or AA genotype (p ‫؍‬ 0.019). Abbreviations: APC ϭ antigen-presenting cell; bp ϭ base pair; CTLA ϭ cytotoxic T-lymphocyte antigen; IL ϭ interleukin; PC 20 ϭ provocative concentration of methacholine causing a 20% fall in FEV 1 ; PCR ϭ polymerase chain reaction; PEF ϭ peak expiratory flow; RFLP ϭ restriction fragment length polymorphism; Th1 ϭ type 1 T-helper; Th2 ϭ type 2 T-helper B ronchial asthma is characterized by the infiltration of inflammatory cells into the airway submucosa. While the precise mechanisms by which inflammatory cells are recruited into the lungs are not fully understood, increasingly available evidence suggests that the activation of antigen-specific CD4ϩ T cells of the type 2 T-helper (Th2) subset in the lungs, which results in interleukin (IL)-5 secretion plays a major role in asthmatic airway inflammation. 1 CD4ϩ T-cell activation leading to cytokine production and effector function requires two signals from the antigen-presenting cell (APC). The first signal is triggered by the interaction between antigen-specific T-cell receptor and peptide-major histocompatibility complex II complexes on APCs. The second signal or "costimulatory" signal is triggered by CD80 (B7-1) and CD86 (B7-2) of the APC binding
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ronchial asthma is characterized by the infiltration of inflammatory cells into the airway submucosa. While the precise mechanisms by which inflammatory cells are recruited into the lungs are not fully understood, increasingly available evidence suggests that the activation of antigen-specific CD4ϩ T cells of the type 2 T-helper (Th2) subset in the lungs, which results in interleukin (IL)-5 secretion plays a major role in asthmatic airway inflammation. 1 CD4ϩ T-cell activation leading to cytokine production and effector function requires two signals from the antigen-presenting cell (APC). The first signal is triggered by the interaction between antigen-specific T-cell receptor and peptide-major histocompatibility complex II complexes on APCs. The second signal or "costimulatory" signal is triggered by CD80 (B7-1) and CD86 (B7-2) of the APC binding to the CD28 and cytotoxic T-lymphocyte antigen (CTLA)-4 of the T lymphocyte. [2] [3] [4] [5] In the absence of costimulatory signals, the T-cell-dependent immune response is greatly diminished, or even eliminated 3, 6, 7 and costimulatory signals may, therefore, fulfill a valuable role in T-lymphocyte activation, type 1 T-helper (Th1) or Th2 cell differentiation, and the production of various cytokines. 7 CTLA-4 is a second costimulatory molecule and is a homolog of CD28. It is expressed only on activated T cells, binds to accessory molecule B7, 8 and mediates T-cell-dependent immune response. Signaling through CTLA-4 may down-regulate Th1 cell proliferation by inhibiting the production of IL-2 and IL-2 receptor expression. 9, 10 However, the role of CTLA-4 remains uncertain, with some studies 8 suggesting that CTLA-4 might also deliver a positive signal to Th2 cell activation. Disruption of this delicate balance of immune regulation could lead to autoimmune diseases or atopic diseases. Therefore, CTLA-4 is considered to be important in the development of many of the immunologic and physiologic features of asthma.
Polymorphisms of the CTLA-4 gene, located on chromosome 2q33, could thus have effects on immune response. The following three CTLA-4 gene polymorphisms are known: a microsatellite (AT)n marker at position 642 of the 3Ј-untranslated region of exon 4; a single-nucleotide polymorphism in exon 1 (adenine or guanine at position ϩ49); and another single-nucleotide polymorphism in the promoter region (cytosine or thymine at position Ϫ318). The A/G dimorphism at exon 1 position ϩ49 results in an amino acid exchange (threonine to alanine) in the leader sequence. [11] [12] [13] To evaluate the possible role of CTLA-4 polymorphisms in bronchial asthma, we investigated the association between two polymorphisms (exon 1 ϩ49 A/G, promoter Ϫ318 C/T) and atopy, asthma severity, and bronchial hyperresponsiveness, in bronchial asthma patients and a healthy control group.
Materials and Methods

Subjects
Eighty-eight consecutive patients with asthma (35 male and 53 female patients), whose ages ranged from 16 to 67 years (mean, 44.2 years), were prospectively studied. The subjects were considered asthmatic if they had a prior clinical history of asthma (as defined by the American Thoracic Society 14 ) for Ն 1 year and had, within the year preceding the study, a history of at least one of the following: (1) a Ͼ 12% reversibility of FEV 1 in response to a bronchodilator; (2) a result of a challenge with a provocative concentration of methacholine causing a 20% fall in FEV 1 (PC 20 ) of Ͻ 8 mg/mL; or (3) a Ͼ 20% maximum within-day amplitude from twice the daily peak expiratory flow (PEF) measurement over a 2-week period. All patients were nonsmokers or exsmokers (for Ͼ 12 months, with Ͻ 5 pack-years).
Eighty-six healthy subjects (19 men and 67 women), whose ages ranged from 22 to 68 years (mean, 46.0 years), were recruited from the employee pool of the Korea University Hospital and graduate students at the College of Medicine, Korea University, and served as control subjects. All control subjects were nonsmokers and had normal findings on chest radiographs, normal airway reactivity, and normal pulmonary function test results. Moreover, they had experienced no current respiratory symptoms, were nonatopic, and had experienced no respiratory infections within the previous month. None were receiving any medications. The study protocol was approved by the ethics committee of the Korea University College of Medicine and written informed consent was obtained from all subjects.
Clinical Assessment
The methacholine challenge was performed using the following method. Acetyl methacholine chloride (Sigma; St. Louis, MO) was diluted with normal saline solution and divided into nine solutions ranging from 0.075 to 25 mg/mL. Each solution was inhaled five times through a nebulizer (DeVilbiss Pulmoaide Compressor/Nebulizer; SM Instruments; Doylestown, PA) and a dosimeter (Micro-Dosimeter; Sunrise Medical; Carlsbad, CA). FEV 1 was measured after each inhalation, and the PC 20 was subsequently calculated from a log response curve by linear interpolation. Positive airway hyperresponsiveness was defined as a PC 20 value of Ͻ 8 mg/mL.
Atopy was defined as a positive reaction to the allergy skinprick test or a total serum IgE level of Ͼ 100 IU/mL. The allergy skin-prick tests were performed using a solution (Bencard; Brentford, England) of 55 common allergen extracts. The ratios of the wheal size compared with that induced by a histamine solution were measured with a skin test reaction gauge (Bencard) 15 min after skin pricking. A negative result of the test indicated that there was no reaction induced by the allergen but that there was a normal reaction to the controlled histamine solution. A score of 1ϩ was given to erythema, and a score of 2ϩ was given to a wheal size ratio of Ͻ 1. Ratios between 1 and 2 were given a score of 3ϩ, and ratios between 2 and 3 were given a 4ϩ. Scores Ͼ 2ϩ were designated as positive. Total serum IgE levels were measured with paper radioimmunosorbent test kits (Radim; Rome, Italy), and levels Ͼ 100 IU/mL were defined as positive.
Classification of asthma severity was based on history, symptoms, clinical features, medication need, FEV 1 , and PEF according to the 1997 Expert Panel Report 2. 15 Asthma severity was classified into mild intermittent, mild persistent, moderate persistent, and severe persistent. The investigator who assessed the severity of asthma was blinded to the genotyping of the CTLA-4 gene.
Genotyping of CTLA-4 Gene
DNA was extracted from peripheral blood leukocytes following standard protocols and column purified (DNA midi kit; Qiagen; Hilden, Germany). The CTLA-4 promoter polymorphism at position Ϫ318 was defined using polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) with Tru9 I restriction enzymes (Bioneer; Seoul, Korea). To amplify the target DNA in the CTLA-4 promoter, PCR was performed with oligonucleotides forward 5Ј-AAATGAATTGGACTGGAT-GGT-3Ј and reverse 5Ј-TTACGAGAAAGGAAGCCGTG-3Ј. 13 A 247-base pair (bp) fragment was amplified by PCR. The following conditions were applied: initial denaturation for 4 min at 94°C, then 30 cycles of 40 s at 94°C, 40 s at 60°C, and 30 s at 72°C. This was followed by a final extension for 4 min at 72°C in a thermal cycler (model 9600; PerkinElmer; Boston, MA). PCR products were further subjected to RFLP analysis with the enzyme Tru9 I (Bioneer) and separated on a 3% agarose gel. PCR fragments with thymine at position Ϫ318 were cut into three fragments (21, 96 , and 130 bp), whereas fragments with cytosine at the same position only had the restriction site at 21 bp. The CTLA-4 exon 1 position 49 (codon 17) polymorphism was defined using PCR-RFLP with the BstEII restriction enzyme (Promega; Madison, WI). PCR was carried out using forward primer 5Ј-AAGGCTCAGCTGAACCTGGT-3Ј and reverse primer 5Ј-CT-GCTGAAACAAATGAAACCC-3Ј. 16 Samples were denatured by 30 cycles of 30 s at 94°C, annealed for 30 s at 58°C, and extended for 30 s at 72°C, using the thermal cycler. A 152-bp fragment containing the ϩ49 A/G polymorphism in exon 1 of CTLA-4 was amplified. The forward primer was designed with a single-base mismatch for the last nucleotide, which corresponded to the ϩ47 position, to introduce a base change in the sequence of the PCR product. This substitution created a BstEII restriction site in the A allele. Amplified products were incubated at 60°C for 2 h using 5 U BstEII per reaction. Digested products underwent electrophoresis on a 3.5% agarose gel. The digested A allele gave a fragment of 130 bp, and the G allele gave an intact 152-bp fragment (Fig 1) .
Statistical Analysis
Statistical analysis was performed using statistical software (SPSS, version 8.0; SPSS; Chicago, IL). The 2 test and t test were used when appropriate.
Results
CTLA-4 Promoter (Ϫ318 C/T) Polymorphism
No deviation from the Hardy-Weinberg equilibrium was observed in any group examined (asthma group, 2 ϭ 0.458 and p ϭ 0.795; control group, 2 ϭ 1.168 and p ϭ 0.558). The distribution of genotypic frequencies was not significantly different for the asthma group and the control group (p ϭ 0.690; Table 1 ). When the asthma group was divided into patients with atopic asthma and nonatopic asthma, the distribution of genotypic frequencies did not differ among the atopic asthma group, the nonatopic asthma group, and the control group (p ϭ 0.311; Table 2 ). The relationships between the CTLA-4 promoter (Ϫ318 C/T) polymorphism and asthma severity were studied. Sixty-one patients were classified as having mild-to-moderate asthma (mild intermittent, 17 patients; mild persistent, 31 patients; moderate persistent, 13 patients), and 27 patients had severe asthma. The distributions of genotypic frequencies were significantly different for the mild-to-moderate group and the severe group. In particular, the frequency of the T allele was 7.4% in the mild-to-moderate group and 20.4% in the severe group, and the association between severe asthma and the T allele was significant (p ϭ 0.037; Table 3 ). The positive predictive value of a positive T allele for severe asthma was 55.0% and the negative predictive value was 72.4%. The relationship between bronchial hyperresponsiveness (PC 20 ) and the CTLA-4 promoter (Ϫ318 C/T) polymorphism was also studied. PC 20 was measured in 45 of the 88 asthma patients, divided into a CC genotype (wild type) group and a CT genotype ϩTT genotype (mutanttype) group. However, PC 20 did not differ between the two groups (p ϭ 0.758; Table 4 ).
CTLA-4 Exon 1 (ϩ49 A/G) Polymorphism
No deviation from the Hardy-Weinberg equilibrium was observed in any group examined (asthma group, 2 ϭ 3.938 and p ϭ 0.140; control group, 2 ϭ 0.585 and p ϭ 0.746). The distribution of genotype frequencies was not different for the asthma group and the control group (p ϭ 0.275; Table 5 ), nor for the atopic asthma group, the nonatopic asthma group, and the control group (p ϭ 0.563; Table 6 ). In addition, the mild-to-moderate asthma group and the severe asthma group did not differ in the distribution of genotype frequencies (p ϭ 0.166; Table 7 ). However, the association between bronchial hyperresponsiveness (PC 20 ) and the CTLA-4 exon 1 (ϩ49 A/G) polymorphism was significant (p ϭ 0.019; Table 8 ). PC 20 was measured in 45 of the 88 asthma patients, classified into a GG genotype (wild-type) group and an AG genotype ϩAA genotype (mutant-type) group. The geometric mean (Ϯ SD) PC 20 in the wild-type group was 2.19 Ϯ 2.12 mg/mL, and in the mutant-type group was 4.51 Ϯ 3.19 mg/mL. From these results, asthmatic patients with the GG genotype had more hyperresponsive airways than did those with the AG or AA genotypes.
Discussion
In this study, the CTLA-4 promoter (Ϫ318 C/T) polymorphism was found to be associated with asthma severity, but not with asthma, atopy, or bronchial hyperresponsiveness. The CTLA-4 exon 1 (ϩ49 A/G) polymorphism was shown to be associated with bronchial hyperresponsiveness, but not with asthma, atopy, or asthma severity. From these results, it appears that the CTLA-4 gene may not be a susceptibility gene, but rather a disease-modifying gene that can modify the asthma phenotype.
There is also increasing evidence that CTLA-4 polymorphisms confer susceptibility to several autoimmune disorders. 17 In particular, the exon 1 (ϩ49 A/G) polymorphism has been found to be associated with type 1 diabetes, 18 Graves disease, 18, 19 and celiac disease. 22 The exon 1 (ϩ49 A/G) GG genotype or the G allele has been found to be associated with type 1 diabetes, 18 Graves diseases, 18, 19 and DR4-positive rheumatoid arthritis. 20 Similarly, the AG genotype has been associated with multiple sclerosis, 21 and the A allele has been associated with celiac disease. 22 In this study, the CTLA-4 exon 1 (ϩ49 A/G) polymorphism was associated with bronchial hyperresponsiveness. Asthmatic patients with the GG genotype had more hyperresponsive airways than did those with the AG or AA genotypes. The manner in which the GG genotype influences bronchial hyperresponsiveness is unclear. In the GG genotype patients, there probably is an increase in CTLA-4 activation. In an ovalbumin-sensitive murine model of asthma, treatment with CTLA-4-Ig significantly reduced the generation of IL-4, IL-5, and IgE, and reduced eosinophilic inflammation in the lungs, as well as reducing bronchial hyperresponsiveness in response to inhaled allergen. 1, 23, 24 In the bronchial explant model, bronchial tissues from atopic asthmatics sensitive to the house dust mite were cultured for 24 h in the presence of house dust mite allergen extract. When CTLA-4-Ig was treated, the expression of IL-5, IL-13, IL-16, and RANTES (regulated on activation, normal T-cell expression and secretion) were reduced, as was T-cell chemotactic activity. 25 Therefore, we can hypothesize that in GG genotype patients, the CTLA-4 is up-regulated, and that this could lead to increased T-cell chemotactic activity and ultimately could result in increased bronchial hyperresponsiveness. Functional studies will be necessary to establish intracellular CTLA-4 expression. The CTLA-4 promoter (Ϫ318 C/T) polymorphism was associated with asthma severity. The frequency of the T allele was 7.4% in the mild-to-moderate group and 20.4% in the severe group, and this association between severe asthma and the T allele was significant (p ϭ 0.037). Asthma severity was determined according to the 1997 Expert Panel Report 2, 15 which included various clinical parameters, such as the degree and frequency of symptoms, the frequency of exacerbation, FEV 1 , and PEF. Therefore, it is difficult to explain how the promoter (Ϫ318 C/T) T allele affects asthma severity. However, it may be useful as a genetic marker of severe asthma. Early recognition of infants at risk for severe asthma by determination of their CTLA-4 promoter (Ϫ318 C/T) T allele followed by close medical follow-up and early environmental or pharmacologic intervention may delay, attenuate, or prevent the progression of disease. 26 In adults identified as "at risk" for severe asthma at the time of diagnosis, closer medical follow-up and early institution of therapy may alter their outcomes. 26 The first possible shortcoming of this study was that the methacholine challenge was performed in only 45 of 88 patients, which would have resulted in a selection bias. The most important reason for not performing the methacholine challenge concerned the patients' respiratory state. It was difficult to perform the test when FEV 1 /FVC was reduced or when symptoms such as cough, dyspnea, and wheezing were present. 27 Another reason was patient refusal. A much larger number of subjects would have to be studied in the future. Second, the male/ female ratio differed significantly between the control group and the asthmatic group. Therefore, we analyzed the association between sex and the polymorphisms (exon 1 ϩ49 A/G, promoter Ϫ318 C/T) in all 174 subjects (54 male subjects and 120 female subjects) in the asthmatic and control groups. For the CTLA-4 promoter (Ϫ318 C/T) polymorphism, the distribution of genotypic frequencies did not differ by sex in all subjects ( think it is possible that the difference in male/female ratios did not influence the conclusion of the study.
In conclusion, the CTLA-4 promoter (Ϫ318 C/T) T allele may serve as a clinically useful marker of severe asthma, and the CTLA-4 exon 1 (ϩ49 A/G) polymorphism may have a disease-modifying effect in asthmatic airways.
